No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients

Malek Zihlif; Suhad Otoum; Mohammad Al Shhab; Zaid Almadani; Monther Momani; Hussam Alhawari; Esraa jibrini; Yazun Jarrar; Hamzeh Al-ameer; Amer Imraish

doi:10.1515/dmpt-2021-0177

Article

No association between LDL receptor and CETP genetic variants and atorvastatin response in Jordanian hyperlipidemic patients

Malek Zihlif , Suhad Otoum , Mohammad Al Shhab , Zaid Almadani , Monther Momani , Hussam Alhawari , Esraa jibrini , Yazun Jarrar , Hamzeh Al-ameer and Amer Imraish

Published/Copyright: April 21, 2022

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 37 Issue 4

Abstract

Objectives

Atorvastatin is commonly used medication to achieve low levels of low-density lipoproteins (LDL). Cholesteryl ester transfer protein (CETP) and LDL receptor (LDLR) genetic variants can affect the cholesterol transport and hence may affect on atorvastatin response. This study aimed to investigate the influence of LDLR AvaII, CETP TaqIb, and Rs1532624 on the efficacy of 20 mg atorvastatin among Jordanian hyperlipidemic patients.

Methods

One hundred and 50 blood samples were collected from hyperlipidemic patients in the University of Jordan Hospital. Polymerase chain reaction-restriction fragment length polymorphism was used for genotyping of LDLR AvaII and CETP TaqIb genetic variants. The genotyping of CETP Rs1532624 variant was done by Sanger DNA-Sequencing.

Results

LDLR AvaII and CETP TaqIb and Rs1532624 variants showed a significant (p value < 0.05) association with the baseline of the LDL at the time of diagnoses. On the other hand, none of the tested genetic variants showed a significant (p value>0.05) association with LDL reduction after atorvastatin therapy.

Conclusions

Results demonstrated a significant association between the LDLR AvaII and CETP TaqIb, and Rs1532624 genetic variants with the LDL baseline level. However, the atorvastatin therapy among hyperlipidemic patients of Jordanian origin was not affected by any of the tested variants.

Keywords: CETP; hyperlipidemia; Jordanians; LDL receptor (LDLR); statins

Corresponding author: Malek Zihlif, PhD, Professor of Pharmacology, Department of Pharmacology, Faculty of Medicine, The University of Jordan, Amman, Jordan, E-mail: m.zihlif@ju.edu.jo

Funding source: The University of Jordan

Award Identifier / Grant number: Unassigned

Acknowledgments

The authors would like to acknowledge The Deanship of Graduate Studies, The University of Jordan, for supporting this research.

Research funding: This work has been funded by The Deanship of Graduate Studies, The University of Jordan.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: The protocol of this study was approved by the Institutional Review Board of The University of Jordan Hospital (with reference number 67/2020/8024).

References

1. Maitland-van der Zee, AH, Klungel, OH, Stricker, BH, Monique Verschuren, WM, Kastelein, JJ, Leufkens, HG, et al.. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002;163:213–22.10.1016/S0021-9150(01)00725-0Search in Google Scholar PubMed

2. Mangravite, LM, Thorn, CF, Krauss, RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006;6:360–74.10.1038/sj.tpj.6500384Search in Google Scholar PubMed

3. Freitas, RN, Khaw, KT, Wu, K, Bowman, R, Jeffery, H, Luben, R, et al.. A single nucleotide polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene ( HMGCR) influences the serum triacylglycerol relationship with dietary fat and fibre in the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. Br J Nutr 2010;104:765–72.10.1017/S0007114510001145Search in Google Scholar PubMed

4. Alhawari, H, Jarrar, Y, AlKhatib, MA, Alhawari, H, Momani, M, Zayed, A, et al.. The association of 3-hydroxy-3-methylglutaryl-CoA reductase, Apolipoprotein E, and solute carrier organic anion genetic variants with Atorvastatin response among Jordanian patients with Type 2 diabetes. Life (Basel) 2020;10:232.10.3390/life10100232Search in Google Scholar PubMed PubMed Central

5. Abdullah, S, Jarrar, Y, Alhawari, H, Abed, E, Zihlif, M. The influence of Endothelial Nitric Oxide Synthase (eNOS) genetic polymorphisms on cholesterol blood levels among Type 2 diabetic patients on Atorvastatin Therapy. Endocr Metab Immune Disord Drug Targets 2021;21:352–9.10.2174/1871530320666200621174858Search in Google Scholar

6. Abed, E, Jarrar, Y, Alhawari, H, Abdullah, S, Zihlif, M. How the cytochrome 7a1 (CYP7A1) and ATP-binding cassette G8 (ABCG8) genetic variants affect atorvastatin response among type 2 diabetic patients attending the University of Jordan Hospital. Int J Clin Pharm Ther 2021;59:99–108.10.5414/CP203779Search in Google Scholar PubMed

7. Postmus, I, Verschuren, JJ, de Craen, AJ, Slagboom, PE, Westendorp, RG, Jukema, JW, et al.. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives. Pharmacogenomics 2012;13:831–40.10.2217/pgs.12.25Search in Google Scholar PubMed

8. Barter, P, Rye, KA. Cholesteryl ester transfer protein: its role in plasma lipid transport. Clin Exp Pharmacol Physiol 1994;21:663–72.10.1111/j.1440-1681.1994.tb02569.xSearch in Google Scholar PubMed

9. Kleber, ME, Grammer, TB, Marz, W. High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning. MMW - Fortschritte Med 2010;152(2 Suppl):47–55.Search in Google Scholar

10. Maitland-van der Zee, AH, Boerwinkle, E. Pharmacogenetics of response to statins: where do we stand? Curr Atherosclerosis Rep 2005;7:204–8.10.1007/s11883-005-0007-3Search in Google Scholar PubMed

11. Frisdal, E, Klerkx, AH, Le Goff, W, Tanck, MW, Lagarde, JP, Jukema, JW, et al.. Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 2005;14:2607–18.10.1093/hmg/ddi291Search in Google Scholar PubMed

12. Lu, H, Inazu, A, Moriyama, Y, Higashikata, T, Kawashiri, MA, Yu, W, et al.. Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism. J Mol Med (Berl) 2003;81:246–55.10.1007/s00109-002-0414-7Search in Google Scholar PubMed

13. Papp, AC, Pinsonneault, JK, Wang, D, Newman, LC, Gong, Y, Johnson, JA, et al.. Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One 2012;7:e31930.10.1371/journal.pone.0031930Search in Google Scholar PubMed PubMed Central

14. Boekholdt, SM, Sacks, FM, Jukema, JW, Shepherd, J, Freeman, DJ, McMahon, AD, et al.. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005;111:278–87.10.1161/01.CIR.0000153341.46271.40Search in Google Scholar PubMed

15. de Grooth, GJ, Zerba, KE, Huang, SP, Tsuchihashi, Z, Kirchgessner, T, Belder, R, et al.. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol 2004;43:854–7.10.1016/j.jacc.2003.08.056Search in Google Scholar PubMed

16. Kaman, D, Ilhan, N, Ilhan, N, Akbulut, M. TaqIB and severity of coronary artery disease in the Turkish population: a pilot study. Bosn J Basic Med Sci 2015;15:9–13.10.17305/bjbms.2015.157Search in Google Scholar PubMed PubMed Central

17. Thompson, A, Di Angelantonio, E, Sarwar, N, Erqou, S, Saleheen, D, Dullaart, RP, et al.. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 2008;299:2777–88.10.1001/jama.299.23.2777Search in Google Scholar PubMed

18. Yehya, A, Irshaid, Y, Saleh, AA. Cholesteryl ester transfer protein rs1532624 gene polymorphism is associated with reduced response to statin therapy. Curr Mol Pharmacol 2013;6:156–62.10.2174/18744672113066660037Search in Google Scholar PubMed

19. Ahn, YI, Kamboh, MI, Aston, CE, Ferrell, RE, Hamman, RF. Role of common genetic polymorphisms in the LDL receptor gene in affecting plasma cholesterol levels in the general population. Arterioscler Thromb 1994;14:663–70.10.1161/01.ATV.14.5.663Search in Google Scholar PubMed

20. Miserez, AR, Rossi, FA, Keller, U. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects. Eur J Clin Pharmacol 1994;46:107–14.10.1007/BF00199871Search in Google Scholar PubMed

21. Streja, L, Packard, CJ, Shepherd, J, Cobbe, S, Ford, I, Group, W. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 2002;90:731–6.10.1016/S0002-9149(02)02599-7Search in Google Scholar PubMed

22. Khalaf, RA, Al-Rawashdeh, S, Sabbah, D, Abu Sheikha, G. Molecular docking and pharmacophore modeling studies of fluorinated benzamides as potential CETP inhibitors. Med Chem 2017;13:239–53.10.2174/1573406412666161104121042Search in Google Scholar PubMed

Received: 2021-09-28

Accepted: 2022-02-04

Published Online: 2022-04-21

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2021-0177

Keywords for this article

CETP; hyperlipidemia; Jordanians; LDL receptor (LDLR); statins